Boston Scientific Q1 2024 Adj EPS $0.56 Beats $0.51 Estimate, Sales $3.856B Beat $3.685B Estimate
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific (NYSE:BSX) reported Q1 2024 adjusted EPS of $0.56, surpassing the $0.51 estimate, and sales of $3.856B, exceeding the $3.685B estimate. This represents a 19.15% increase in earnings and a 13.78% increase in sales from the same period last year.
April 24, 2024 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific reported a strong Q1 2024 with earnings and sales surpassing estimates, indicating robust financial health and growth.
The significant beat on both earnings and sales estimates for Q1 2024 suggests that Boston Scientific is performing better than expected, which could lead to positive investor sentiment and a potential increase in stock price in the short term. The year-over-year growth in earnings and sales further reinforces the company's upward trajectory, making it an attractive asset for investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100